Quality of life of brazilian patients with gaucher disease and fabry disease

JIMD Reports

Volumn 7, Issue , 2013, Pages 31-37

  Oliveira, Fabiane Lopes ^a   Alegra, Taciane ^a   Dornelles, Alicia ^b   Krug, Bárbara Corrêa ^a   Netto, Cristina B O ^b   da Rocha, Neusa Sica ^a   Picon, Paulo D ^b   Schwartz, Ida Vanessa D ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Enzyme replacement therapy; Fabry disease; Gauche disease; Mental component score; Physical component score

Indexed keywords

EID: 84886851749     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2012_136     Document Type: Chapter

References (24)

1. Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR (1997) Brazilian-Portuguese version of the SF-36. A reliable and valid quality of life outcome measure. Rev Bras Reumatol 39:50
2. Damiano AM, Pastores GM, Ware JE (1998) The health-related quality of life of adults with Gaucher’s disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 7:373–386
3. Gieselmann V (1995) Lysosomal storage diseases. Biochim Biophys Acta 1270:103–136
4. Giraldo P, Pocoví M, Pérez-Calvo J, Rubio-Félix D, Giralt M (2000) Report of the Spanish Gaucher’s Disease Registry: clinical and genetic characteristics. Haematologica 85:792–799
5. Giraldo P, Solano V, Pérez-Calvo JI, Giralt M, Rubio-Félix D, Spanish Group on Gaucher Disease (2005) Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 14:453–462
6. Hsiung PC, Fang CT, Chang YY, Chen MY, Wang JD (2005) Comparison of WHOQOL-bREF and SF-36 in patients with HIV infection. Qual Life Res 14:141–150
7. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr (2000) Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 43:1478–1487
8. Lima MG, Barros MB, Cesar CL, Goldbaum M, Carandina L, Ciconelli RM (2009) Health related quality of life among the elderly: a population-based study using SF-36 survey. Cad Saude Publica 25:2159–2167
9. Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK (1999) Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res 8:263–268
10. McHorney CA, Ware JE Jr, Raczek AE (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247–263
11. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999a) Prevalence of lysosomal storage disorders. JAMA 281:249–254
12. Meikle PJ, Ranieri E, Ravenscroft EM, Hua CT, Brooks DA, Hopwood JJ (1999b) Newborn screening for lysosomal storage disorders. Southeast Asian J Trop Med Public Health 30(Suppl 2):104–110
13. Panzini RG, Bandeira DR (2005) Quality of life and spiritual-religious coping relations. Qual Life Res 14:2106–2107
14. Pastores GM, Barnett NL, Bathan P, Kolodny EH (2003) A neurological symptom survey of patients with type I Gaucher disease. J Inherit Metab Dis 26:641–645
15. Pinto LL, Vieira TA, Giugliani R, Schwartz IV (2010) Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review. Orphanet J Rare Dis 5:14
16. Poorthuis BJ, Wevers RA, Kleijer WJ et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151–156
17. Raas-Rothschild A, Pankova-Kholmyansky I, Kacher Y, Futerman AH (2004) Glycosphingolipidoses: beyond the enzymatic defect. Glycoconj J 21:295–304
18. Streiner DL, Norman GR (1995) Health measurement scales: a practical guide to their development and use. Oxford University Press, Oxford
19. The WHOQOL Group (1994) Development of the WHOQOL: rationale and current status. Int J Ment Health 23:24–56
20. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483
21. Ware JE, Snow KK, Kosinski M et al (1993) SF-36 health survey. Manual and interpretation guide. New England Medical Center, Boston
22. Weinreb N, Barranger J, Packman S et al (2007) Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 71:576–588
23. Wraith JE (2002) Lysosomal disorders. Semin Neonatol 7:75–83
24. Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, Beutler E (1992) Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine 71:337–53